Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Merck
Scientific Title
A phase 3 randomised, double blind study of pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin as first-line therapy in participants with advanced and/or unresctable biliary tract carcinoma